News articles about Bioamber (NYSE:BIOA) have been trending somewhat negative this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioamber earned a media sentiment score of -0.02 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.2172020400877 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s rankings:
- White Biotechnology Market to touch new level in near future – Players involved in the study Amyris, Gevo, BioAmber, Deinove (digitaljournal.com)
- BioAmber Inc (markets.ft.com)
- Constructive Market Analysis Of United States 1, 4-Butanediol (BDO) : Forecast Period 2018-2025 (tokenquire.com)
- Methodological Understanding Of The United States 1, 4-Butanediol (BDO) Market 2018-2025: A Questale Report (tokendesks.com)
- United States 1, 4-Butanediol (BDO) Market Analysis 2018-2025: Questale Report (bitzradar.com)
A number of equities analysts have commented on the stock. HC Wainwright reduced their target price on shares of Bioamber from $12.00 to $1.75 and set a “buy” rating on the stock in a research note on Thursday, March 29th. ValuEngine downgraded shares of Bioamber from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research raised shares of Bioamber from a “sell” rating to a “hold” rating in a research note on Monday, February 19th.
Bioamber (NYSE:BIOA) last released its quarterly earnings results on Tuesday, March 27th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11. The business had revenue of $5.40 million for the quarter, compared to the consensus estimate of $6.49 million. Bioamber had a negative net margin of 238.43% and a negative return on equity of 48.72%. research analysts anticipate that Bioamber will post -0.53 EPS for the current fiscal year.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.